Eisuke Fukuma, MD

Articles by Eisuke Fukuma, MD

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

ByMamoru Fukuda, MD,Susumu Yamaguchi, MD,Tomohiko Ohta, MD,Yoshiaki Nakayama, MD,Haruki Ogata, MD,Kaname Shimizu, MD,Toru Nishikawa, MD,Yukihiro Adachi, MD,Eisuke Fukuma, MD

July 1st 1999

We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), uracil and tegafur (UFT), and tamoxifen (Nolvadex) (CAUT), designed as

Latest Updated Articles

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen
July 1st 1999

Trending on CancerNetwork

124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis